Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

Finally, in the patient (patient 7) who met inclusion criteria but did not receive rituximab due to a complete response to corticosteroids, the clinical response was associated with a highly significant reduction of autoantibody titers after 1 year ( figure 2B ).

also in 132,142 other papers